| |  Online-Ressource |
|---|
| Verfasst von: | Marlais, Matko [VerfasserIn]  |
|---|
| | Wlodkowski, Tanja [VerfasserIn] |
|---|
| | Al-Akash, Samhar [VerfasserIn] |
|---|
| | Ananin, Petr [VerfasserIn] |
|---|
| | Bandi, Varun Kumar [VerfasserIn] |
|---|
| | Baudouin, Veronique [VerfasserIn] |
|---|
| | Boyer, Olivia [VerfasserIn] |
|---|
| | Vásquez, Luciola [VerfasserIn] |
|---|
| | Govindan, Sukanya [VerfasserIn] |
|---|
| | Hooman, Nakysa [VerfasserIn] |
|---|
| | Ijaz, Iftikhar [VerfasserIn] |
|---|
| | Loza, Reyner [VerfasserIn] |
|---|
| | Melgosa, Marta [VerfasserIn] |
|---|
| | Pande, Nivedita [VerfasserIn] |
|---|
| | Pape, Lars [VerfasserIn] |
|---|
| | Saha, Anshuman [VerfasserIn] |
|---|
| | Samsonov, Dmitry [VerfasserIn] |
|---|
| | Schreuder, Michiel F. [VerfasserIn] |
|---|
| | Sharma, Jyoti [VerfasserIn] |
|---|
| | Siddiqui, Sahar [VerfasserIn] |
|---|
| | Sinha, Rajiv [VerfasserIn] |
|---|
| | Stewart, Heather [VerfasserIn] |
|---|
| | Tasic, Velibor [VerfasserIn] |
|---|
| | Tönshoff, Burkhard [VerfasserIn] |
|---|
| | Twombley, Katherine [VerfasserIn] |
|---|
| | Upadhyay, Kiran [VerfasserIn] |
|---|
| | Vivarelli, Marina [VerfasserIn] |
|---|
| | Weaver, Donald J. [VerfasserIn] |
|---|
| | Woroniecki, Robert [VerfasserIn] |
|---|
| | Schaefer, Franz [VerfasserIn] |
|---|
| | Tullus, Kjell [VerfasserIn] |
|---|
| Titel: | COVID-19 in children treated with immunosuppressive medication for kidney diseases |
|---|
| Verf.angabe: | Matko Marlais, Tanja Wlodkowski, Samhar Al-Akash, Petr Ananin, Varun Kumar Bandi, Veronique Baudouin, Olivia Boyer, Luciola Vásquez, Sukanya Govindan, Nakysa Hooman, Iftikhar Ijaz, Reyner Loza, Marta Melgosa, Nivedita Pande, Lars Pape, Anshuman Saha, Dmitry Samsonov, Michiel F. Schreuder, Jyoti Sharma, Sahar Siddiqui, Rajiv Sinha, Heather Stewart, Velibor Tasic, Burkhard Tönshoff, Katherine Twombley, Kiran Upadhyay, Marina Vivarelli, Donald J. Weaver, Robert Woroniecki, Franz Schaefer, Kjell Tullus |
|---|
| Jahr: | 2021 |
|---|
| Umfang: | 4 S. |
|---|
| Fussnoten: | Published Online First 21 December 2020 ; Gesehen am 14.10.2021 |
|---|
| Titel Quelle: | Enthalten in: Archives of disease in childhood |
|---|
| Ort Quelle: | London : BMJ Publ. Group, 1926 |
|---|
| Jahr Quelle: | 2021 |
|---|
| Band/Heft Quelle: | 106(2021), 8, Seite 798-801 |
|---|
| ISSN Quelle: | 1468-2044 |
|---|
| Abstract: | Background Children are recognised as at lower risk of severe COVID-19 compared with adults, but the impact of immunosuppression is yet to be determined. This study aims to describe the clinical course of COVID-19 in children with kidney disease taking immunosuppressive medication and to assess disease severity. - Methods Cross-sectional study hosted by the European Rare Kidney Disease Reference Network and supported by the European, Asian and International paediatric nephrology societies. Anonymised data were submitted online for any child (age <20 years) with COVID-19 taking immunosuppressive medication for a kidney condition. Study recruited for 16 weeks from 15 March 2020 to 05 July 2020. The primary outcome was severity of COVID-19. - Results 113 children were reported in this study from 30 different countries. Median age: 13 years (49% male). Main underlying reasons for immunosuppressive therapy: kidney transplant (47%), nephrotic syndrome (27%), systemic lupus erythematosus (10%). Immunosuppressive medications used include: glucocorticoids (76%), mycophenolate mofetil (MMF) (54%), tacrolimus/ciclosporine A (58%), rituximab/ofatumumab (11%). 78% required no respiratory support during COVID-19 illness, 5% required bi-level positive airway pressure or ventilation. Four children died; all deaths reported were from low-income countries with associated comorbidities. There was no significant difference in severity of COVID-19 based on gender, dialysis status, underlying kidney condition, and type or number of immunosuppressive medications. - Conclusions This global study shows most children with a kidney disease taking immunosuppressive medication have mild disease with SARS-CoV-2 infection. We therefore suggest that children on immunosuppressive therapy should not be more strictly isolated than children who are not on immunosuppressive therapy. |
|---|
| DOI: | doi:10.1136/archdischild-2020-320616 |
|---|
| URL: | Bitte beachten Sie: Dies ist ein Bibliographieeintrag. Ein Volltextzugriff für Mitglieder der Universität besteht hier nur, falls für die entsprechende Zeitschrift/den entsprechenden Sammelband ein Abonnement besteht oder es sich um einen OpenAccess-Titel handelt.
Volltext ; Verlag: https://doi.org/10.1136/archdischild-2020-320616 |
|---|
| | Volltext: https://adc.bmj.com/content/106/8/798 |
|---|
| | DOI: https://doi.org/10.1136/archdischild-2020-320616 |
|---|
| Datenträger: | Online-Ressource |
|---|
| Sprache: | eng |
|---|
| Sach-SW: | nephrology |
|---|
| | virology |
|---|
| K10plus-PPN: | 1773871617 |
|---|
| Verknüpfungen: | → Zeitschrift |
|---|
COVID-19 in children treated with immunosuppressive medication for kidney diseases / Marlais, Matko [VerfasserIn]; 2021 (Online-Ressource)
